Advertisement
Advertisement

BBIO

BBIO logo

BridgeBio Pharma, Inc. Common Stock

66.26
USD
Sponsored
-2.19
-3.20%
May 29, 16:00 UTC -4
Closed
exchange

After-Market

66.35

+0.09
+0.13%

BBIO Earnings Reports

Positive Surprise Ratio

BBIO beat 8 of 28 last estimates.

29%

Next Report

Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$228.74M
/
-$0.59
Implied change from Q1 26 (Revenue/ EPS)
+17.59%
/
-29.76%
Implied change from Q2 25 (Revenue/ EPS)
+106.88%
/
-37.89%

BridgeBio Pharma, Inc. Common Stock earnings per share and revenue

On May 07, 2026, BBIO reported earnings of -0.84 USD per share (EPS) for Q1 26, missing the estimate of -0.69 USD, resulting in a -21.37% surprise. Revenue reached 194.51 million, compared to an expected 181.50 million, with a 7.17% difference. The market reacted with a -0.09% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 13 analysts forecast an EPS of -0.59 USD, with revenue projected to reach 228.74 million USD, implying an decrease of -29.76% EPS, and increase of 17.59% in Revenue from the last quarter.
FAQ
For Q1 2026, BridgeBio Pharma, Inc. Common Stock reported EPS of -$0.84, missing estimates by -21.37%, and revenue of $194.51M, 7.17% above expectations.
The stock price moved down -0.09%, changed from $67.45 before the earnings release to $67.39 the day after.
The next earning report is scheduled for Aug 03, 2026.
Based on 13 analysts, BridgeBio Pharma, Inc. Common Stock is expected to report EPS of -$0.59 and revenue of $228.74M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement